rmhTNF联合顺铂腔内注射治疗恶性浆膜腔积液的临床观察  

Clinical Observation of rmhTNF and Cisplatin in the Treatment of Malignant Serous Effusion

作　　者：陈剑波 

机构地区：[1]厦门大学附属第一医院厦门市肿瘤医院,福建厦门361003

出　　处：《中外医学研究》2017年第32期4-6,共3页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:评价重组改构人肿瘤坏死因子(rmhTNF)联合顺铂治疗恶性浆膜腔积液的疗效、安全性和对患者生活质量的影响。方法:选取2011年8月-2015年7月笔者所在医院肿瘤内科收住院的符合本研究标准的中晚期恶性肿瘤合并恶性浆膜腔积液的患者83例,采用信封法随机抽取分为两组,试验组38例,对照组45例。试验组抽取浆膜腔积液后腔内灌注顺铂50 mg/m^2及rmhTNF 150万单位,对照组抽取浆膜腔积液后采用顺铂50 mg/m^2单药灌注。观察比较两组患者的临床疗效、不良反应及生活质量。结果:试验组治疗有效率为84.2%(32/38),高于对照组的64.4%(29/45),比较差异有统计学意义(P<0.05);试验组患者治疗后1周KPS评分较治疗前均明显改善,比较差异均有统计学意义(P<0.05);不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。结论:rmhTNF联合顺铂腔内注射治疗恶性浆膜腔积液可取得更加满意的疗效,有效提高疾病控制率,改善患者生活质量,值得临床推广。Objective：To evaluate the efficacy and safety of recombinant human tumor necrosis factor（rmhTNF）and its effect on the quality of life of patients.Method：From August 2011 to July 2015,83 patients with advanced malignant neoplasm associated with malignant serous effusion admitted to our hospital for oncology were randomly divided into two groups according to the envelope method,38 in the experimental group and 45 in the control group.Patients in the experimental group were perfused with 50 mg/m^2 of Cisplatin and 1.5 million units of rmhTNF;patients in the control group were perfused with 50 mg/m^2 of Cisplatin.The therapeutic effect,adverse reactions and quality of life were observed and compared between the two groups.Result：The effective rate of the treatment group was 84.2%（32/38）,which was higher than 64.4%（29/45） of the control group,the difference was statistically significant（P〈0.05）.The KPS score of the experimental group was significantly improved 1 week after treatment compared with before treatment,the difference was statistically significant（P〈0.05）;there was no significant difference in the incidence of adverse reactions between the two groups（P〉0.05）.Conclusion：rmh TNF combined with cisplatin in the treatment of malignant serous effusion can achieve more satisfactory curative effect,effectively the disease control rate and improve quality of life of patients,worthy of clinical promotion.

关 键 词：恶性浆膜腔积液 肿瘤 重组改构人肿瘤坏死因子 联合 

分 类 号：R730.5[医药卫生—肿瘤]